<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01847274</url>
  </required_header>
  <id_info>
    <org_study_id>213356</org_study_id>
    <secondary_id>PR-30-5011-C</secondary_id>
    <nct_id>NCT01847274</nct_id>
  </id_info>
  <brief_title>A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer</brief_title>
  <official_title>A Phase 3 Randomized Double-blind Trial of Maintenance With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tesaro, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Network of Gynaecological Oncological Trial Groups (ENGOT)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Myriad Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>US Oncology Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sarah Cannon</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cooperative Ovarian Cancer Group (COGI)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Facing Our Risk of Cancer Empowered</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tesaro, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study of
      niraparib as maintenance in platinum sensitive ovarian cancer patients who have either
      gBRCAmut or a tumor with high-grade serous histology and who have responded to their most
      recent chemotherapy containing a platinum agent. Niraparib is an orally active PARP
      inhibitor. Niraparib or placebo (in a 2:1 ratio) will be administered once daily continuously
      during a 28-day cycle. Health-related quality of life will be measured by the Functional
      Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI), European Quality of Life scale,
      5-Dimensions (EQ-5D), and a neuropathy questionnaire. Safety and tolerability will be
      assessed by clinical review of adverse events (AEs), physical examinations,
      electrocardiograms (ECGs), and safety laboratory values.

      The primary objective of this study is to evaluate efficacy of niraparib as maintenance
      therapy in patients who have platinum sensitive ovarian cancer as assessed by the
      prolongation of progression free survival (PFS).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 21, 2013</start_date>
  <completion_date type="Anticipated">December 14, 2020</completion_date>
  <primary_completion_date type="Actual">June 30, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS) in Cohort With Germline BRCA Mutation (gBRCA)</measure>
    <time_frame>From date of randomization to the earliest date of disease progression or death from any cause.</time_frame>
    <description>PFS was defined as the time between randomization and disease progression or death from any cause. Computed tomography or magnetic resonance imaging to assess disease progression was performed at baseline, every 8 weeks through cycle 14, and then every 12 weeks until treatment discontinuation. The objective assessment of disease progression was determined by means of central radiologic and clinical review, according to Response Evaluation Criteria in Solid Tumors (RECIST),version 1.1, which was performed in a blinded fashion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS) in Cohort With No Germline BCRA With Homologous Recombination Deficiency-positive (HRD+) Tumors (Non-gBRCAmut HRD+)</measure>
    <time_frame>From date of randomization to the earliest date of disease progression or death from any cause</time_frame>
    <description>PFS was defined as the time between randomization and disease progression or death from any cause. Computed tomography or magnetic resonance imaging to assess disease progression was performed at baseline, every 8 weeks through cycle 14, and then every 12 weeks until treatment discontinuation. The objective assessment of disease progression was determined by means of central radiologic and clinical review, according to Response Evaluation Criteria in Solid Tumors (RECIST),version 1.1, which was performed in a blinded fashion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS) in Cohort With No Germline BRCA Mutation (Non-gBRCA)</measure>
    <time_frame>From date of randomization to the earliest date of disease progression or death from any cause.</time_frame>
    <description>PFS was defined as the time between randomization and disease progression or death from any cause. Computed tomography or magnetic resonance imaging to assess disease progression was performed at baseline, every 8 weeks through cycle 14, and then every 12 weeks until treatment discontinuation. The objective assessment of disease progression was determined by means of central radiologic and clinical review, according to Response Evaluation Criteria in Solid Tumors (RECIST),version 1.1, which was performed in a blinded fashion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to First Subsequent Therapy (TFST) in Cohort With Germline BRCA Mutation (gBRCA)</measure>
    <time_frame>From date of randomization to the earliest date of first subsequent therapy or death.</time_frame>
    <description>Patients were to be followed off treatment every 3 months for subsequent anti-cancer treatment. The TFST was defined as the time from the date of randomization to the start date of the first subsequent anti-cancer therapy or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Subsequent Therapy (TFST) in Cohort With No Germline BRCA Mutation (Non-gBRCA)</measure>
    <time_frame>From date of randomization to the earliest date of first subsequent therapy or death.</time_frame>
    <description>Patients were to be followed off treatment every 3 months for subsequent anti-cancer treatment. The TFST was defined as the time from the date of randomization to the start date of the first subsequent anti-cancer therapy or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemotherapy-Free Interval (CFI) in Cohort With Germline BRCA Mutation (gBRCA)</measure>
    <time_frame>From date of last platinum therapy prior to randomization to the initiation of the next anti-cancer therapy after maintenance treatment.</time_frame>
    <description>CFI was defined as the time from the last platinum therapy prior to randomization to the initiation of the next anti-cancer therapy after maintenance treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemotherapy-Free Interval (CFI) in Cohort With No Germline BRCA Mutation (Non-gBRCA)</measure>
    <time_frame>From date of last platinum therapy prior to randomization to the initiation of the next anti-cancer therapy after maintenance treatment.</time_frame>
    <description>CFI was defined as the time from the last platinum therapy prior to randomization to the initiation of the next anti-cancer therapy after maintenance treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival 2 (PFS2) in Cohort With Germline BRCA Mutation (gBRCA)</measure>
    <time_frame>From treatment randomization to the earlier of the date of disease progression on the next anti-cancer therapy following study treatment or death due to any cause.</time_frame>
    <description>Patients were to be followed off treatment every 3 months for subsequent anti-cancer treatment, including outcome of such therapy, any new malignancies, and survival status. PFS2 was defined as the time from treatment randomization to the earlier of the date of disease progression on the next anti-cancer therapy following study treatment or death due to any cause. This study is ongoing, PFS2 is immature at this stage of primary analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival 2 (PFS2) in Cohort With No Germline BRCA Mutation (Non-gBRCA)</measure>
    <time_frame>From treatment randomization to the earlier of the date of disease progression on the next anti-cancer therapy following study treatment or death due to any cause.</time_frame>
    <description>Patients were to be followed off treatment every 3 months for subsequent anti-cancer treatment, including outcome of such therapy, any new malignancies, and survival status. PFS2 was defined as the time from treatment randomization to the earlier of the date of disease progression on the next anti-cancer therapy following study treatment or death due to any cause. This study is ongoing, PFS2 is immature at this stage of primary analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) in Cohort With Germline BRCA Mutation (gBRCA)</measure>
    <time_frame>From treatment randomization to date of death by any cause</time_frame>
    <description>Patients were to be followed off treatment every 3 months for survival status. Overall survival is defined as the date of randomization to the date of death by any cause. Results not yet reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) in Cohort With No Germline BRCA Mutation (Non-gBRCA)</measure>
    <time_frame>From treatment randomization to date of death by any cause</time_frame>
    <description>Patients were to be followed off treatment every 3 months for survival status. Overall survival is defined as the date of randomization to the date of death by any cause. Results not yet reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Second Subsequent Therapy (TSST) in Cohort With Germline BRCA Mutation (gBRCA)</measure>
    <time_frame>From the date of randomization to the start date of the second subsequent anti-cancer therapy.</time_frame>
    <description>Patients were to be followed off treatment every 3 months for subsequent anti-cancer treatment, including outcome of such therapy, any new malignancies, and survival status. TSST is defined as the date of randomization to the earlier of the start date of second follow-up anti-cancer treatment or death. Results not yet reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Second Subsequent Therapy (TSST) in Cohort With No Germline BRCA Mutation (Non-gBRCA)</measure>
    <time_frame>From the date of randomization to the start date of the second subsequent anti-cancer therapy.</time_frame>
    <description>Patients were to be followed off treatment every 3 months for subsequent anti-cancer treatment, including outcome of such therapy, any new malignancies, and survival status. TSST is defined as the date of randomization to the earlier of the start date of second follow-up anti-cancer treatment or death. Results not yet reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) in Cohort With Germline BRCA</measure>
    <time_frame>At Cycle 2</time_frame>
    <description>The FOSI is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Patients respond to their symptom experience over the past 7 days using a 5-point Likert scale. The total symptom index is calculated as the total of the 8 scores, ranging from 0 (&quot;severely symptomatic&quot;) to 32 (&quot;asymptomatic&quot;). A positive change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) in Cohort With Germline BRCA</measure>
    <time_frame>At Cycle 4</time_frame>
    <description>The FOSI is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Patients respond to their symptom experience over the past 7 days using a 5-point Likert scale. The total symptom index is calculated as the total of the 8 scores, ranging from 0 (&quot;severely symptomatic&quot;) to 32 (&quot;asymptomatic&quot;). A positive change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) in Cohort With Germline BRCA</measure>
    <time_frame>At Cycle 6</time_frame>
    <description>The FOSI is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Patients respond to their symptom experience over the past 7 days using a 5-point Likert scale. The total symptom index is calculated as the total of the 8 scores, ranging from 0 (&quot;severely symptomatic&quot;) to 32 (&quot;asymptomatic&quot;). A positive change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) in Cohort With Germline BRCA</measure>
    <time_frame>At Post Progression</time_frame>
    <description>The FOSI is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Patients respond to their symptom experience over the past 7 days using a 5-point Likert scale. The total symptom index is calculated as the total of the 8 scores, ranging from 0 (&quot;severely symptomatic&quot;) to 32 (&quot;asymptomatic&quot;). A positive change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) in Cohort With no Germline BRCA</measure>
    <time_frame>At Cycle 2</time_frame>
    <description>The FOSI is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Patients respond to their symptom experience over the past 7 days using a 5-point Likert scale. The total symptom index is calculated as the total of the 8 scores, ranging from 0 (&quot;severely symptomatic&quot;) to 32 (&quot;asymptomatic&quot;). A positive change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) in Cohort With no Germline BRCA</measure>
    <time_frame>At Cycle 4</time_frame>
    <description>The FOSI is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Patients respond to their symptom experience over the past 7 days using a 5-point Likert scale. The total symptom index is calculated as the total of the 8 scores, ranging from 0 (&quot;severely symptomatic&quot;) to 32 (&quot;asymptomatic&quot;). A positive change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) in Cohort With no Germline BRCA</measure>
    <time_frame>At Cycle 6</time_frame>
    <description>The FOSI is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Patients respond to their symptom experience over the past 7 days using a 5-point Likert scale. The total symptom index is calculated as the total of the 8 scores, ranging from 0 (&quot;severely symptomatic&quot;) to 32 (&quot;asymptomatic&quot;). A positive change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) in Cohort With no Germline BRCA</measure>
    <time_frame>At Post Progression</time_frame>
    <description>The FOSI is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Patients respond to their symptom experience over the past 7 days using a 5-point Likert scale. The total symptom index is calculated as the total of the 8 scores, ranging from 0 (&quot;severely symptomatic&quot;) to 32 (&quot;asymptomatic&quot;). A positive change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in EQ-5D-5L in Cohort With Germline BRCA</measure>
    <time_frame>At Cycle 2</time_frame>
    <description>EQ-5D-5L is a well-validated, general preference-based, health-related QoL instrument. The EQ-5D-5L encompasses 5 domains, asking patients to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: &quot;no problems&quot; (Level 1), &quot;slight problems&quot; (Level 2), &quot;moderate problems&quot; (Level 3), &quot;severe problems&quot; (Level 4), and &quot;extreme problems&quot; (Level 5). Each domain is assigned a level, and levels are combined to create a 5-digit number describing the patient's health state. For each patient, an index value is determined from a published country-specific value set. This index value or utility score ranges from 0 to 1.00 (with 1.0 representing perfect health) and is used in the calculation of quality-adjusted life years (QALYs) that are used to inform economic valuations of health interventions. A positive change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in EQ-5D-5L in Cohort With Germline BRCA</measure>
    <time_frame>At Cycle 4</time_frame>
    <description>EQ-5D-5L is a well-validated, general preference-based, health-related QoL instrument. The EQ-5D-5L encompasses 5 domains, asking patients to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: &quot;no problems&quot; (Level 1), &quot;slight problems&quot; (Level 2), &quot;moderate problems&quot; (Level 3), &quot;severe problems&quot; (Level 4), and &quot;extreme problems&quot; (Level 5). Each domain is assigned a level, and levels are combined to create a 5-digit number describing the patient's health state. For each patient, an index value is determined from a published country-specific value set. This index value or utility score ranges from 0 to 1.00 (with 1.0 representing perfect health) and is used in the calculation of quality-adjusted life years (QALYs) that are used to inform economic valuations of health interventions. A positive change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in EQ-5D-5L in Cohort With Germline BRCA</measure>
    <time_frame>At Cycle 6</time_frame>
    <description>EQ-5D-5L is a well-validated, general preference-based, health-related QoL instrument. The EQ-5D-5L encompasses 5 domains, asking patients to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: &quot;no problems&quot; (Level 1), &quot;slight problems&quot; (Level 2), &quot;moderate problems&quot; (Level 3), &quot;severe problems&quot; (Level 4), and &quot;extreme problems&quot; (Level 5). Each domain is assigned a level, and levels are combined to create a 5-digit number describing the patient's health state. For each patient, an index value is determined from a published country-specific value set. This index value or utility score ranges from 0 to 1.00 (with 1.0 representing perfect health) and is used in the calculation of quality-adjusted life years (QALYs) that are used to inform economic valuations of health interventions. A positive change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in EQ-5D-5L in Cohort With Germline BRCA</measure>
    <time_frame>At Post Progression</time_frame>
    <description>EQ-5D-5L is a well-validated, general preference-based, health-related QoL instrument. The EQ-5D-5L encompasses 5 domains, asking patients to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: &quot;no problems&quot; (Level 1), &quot;slight problems&quot; (Level 2), &quot;moderate problems&quot; (Level 3), &quot;severe problems&quot; (Level 4), and &quot;extreme problems&quot; (Level 5). Each domain is assigned a level, and levels are combined to create a 5-digit number describing the patient's health state. For each patient, an index value is determined from a published country-specific value set. This index value or utility score ranges from 0 to 1.00 (with 1.0 representing perfect health) and is used in the calculation of quality-adjusted life years (QALYs) that are used to inform economic valuations of health interventions. A positive change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in EQ-5D-5L in Cohort With no Germline BRCA</measure>
    <time_frame>At Cycle 2</time_frame>
    <description>EQ-5D-5L is a well-validated, general preference-based, health-related QoL instrument. The EQ-5D-5L encompasses 5 domains, asking patients to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: &quot;no problems&quot; (Level 1), &quot;slight problems&quot; (Level 2), &quot;moderate problems&quot; (Level 3), &quot;severe problems&quot; (Level 4), and &quot;extreme problems&quot; (Level 5). Each domain is assigned a level, and levels are combined to create a 5-digit number describing the patient's health state. For each patient, an index value is determined from a published country-specific value set. This index value or utility score ranges from 0 to 1.00 (with 1.0 representing perfect health) and is used in the calculation of quality-adjusted life years (QALYs) that are used to inform economic valuations of health interventions. A positive change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in EQ-5D-5L in Cohort With no Germline BRCA</measure>
    <time_frame>At Cycle 4</time_frame>
    <description>EQ-5D-5L is a well-validated, general preference-based, health-related QoL instrument. The EQ-5D-5L encompasses 5 domains, asking patients to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: &quot;no problems&quot; (Level 1), &quot;slight problems&quot; (Level 2), &quot;moderate problems&quot; (Level 3), &quot;severe problems&quot; (Level 4), and &quot;extreme problems&quot; (Level 5). Each domain is assigned a level, and levels are combined to create a 5-digit number describing the patient's health state. For each patient, an index value is determined from a published country-specific value set. This index value or utility score ranges from 0 to 1.00 (with 1.0 representing perfect health) and is used in the calculation of quality-adjusted life years (QALYs) that are used to inform economic valuations of health interventions. A positive change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in EQ-5D-5L in Cohort With no Germline BRCA</measure>
    <time_frame>At Cycle 6</time_frame>
    <description>EQ-5D-5L is a well-validated, general preference-based, health-related QoL instrument. The EQ-5D-5L encompasses 5 domains, asking patients to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: &quot;no problems&quot; (Level 1), &quot;slight problems&quot; (Level 2), &quot;moderate problems&quot; (Level 3), &quot;severe problems&quot; (Level 4), and &quot;extreme problems&quot; (Level 5). Each domain is assigned a level, and levels are combined to create a 5-digit number describing the patient's health state. For each patient, an index value is determined from a published country-specific value set. This index value or utility score ranges from 0 to 1.00 (with 1.0 representing perfect health) and is used in the calculation of quality-adjusted life years (QALYs) that are used to inform economic valuations of health interventions. A positive change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in EQ-5D-5L in Cohort With no Germline BRCA</measure>
    <time_frame>At Post Progression</time_frame>
    <description>EQ-5D-5L is a well-validated, general preference-based, health-related QoL instrument. The EQ-5D-5L encompasses 5 domains, asking patients to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: &quot;no problems&quot; (Level 1), &quot;slight problems&quot; (Level 2), &quot;moderate problems&quot; (Level 3), &quot;severe problems&quot; (Level 4), and &quot;extreme problems&quot; (Level 5). Each domain is assigned a level, and levels are combined to create a 5-digit number describing the patient's health state. For each patient, an index value is determined from a published country-specific value set. This index value or utility score ranges from 0 to 1.00 (with 1.0 representing perfect health) and is used in the calculation of quality-adjusted life years (QALYs) that are used to inform economic valuations of health interventions. A positive change from baseline indicates improvement.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">553</enrollment>
  <condition>Ovarian Neoplasms</condition>
  <condition>Platinum Sensitive Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Niraparib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2:1 Ratio administered once daily continuously during a 28 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administered once daily continuously over a 28 day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active comparator: Niraparib</intervention_name>
    <description>Niraparib vs placebo 2:1 ratio</description>
    <arm_group_label>Niraparib</arm_group_label>
    <other_name>Niraparib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older, female, any race

          -  Histologically diagnosed ovarian cancer, fallopian tube cancer or primary peritoneal
             cancer

          -  High grade (or grade 3) serous histology or known to have gBRCAmut

          -  Has received at least 2 previous courses of platinum-containing therapy, and has
             disease that was considered platinum sensitive following the penultimate (next to
             last) platinum course (more than 6 month period between penultimate platinum regimen
             and progression of disease)

          -  Has responded to last the platinum regimen, remains in response and is enrolled on
             study within 8 weeks of completion of the last platinum regimen

          -  ECOG 0-1

          -  Adequate bone marrow, kidney and liver function

        Exclusion Criteria:

          -  Known hypersensitivity to the components of niraparib

          -  Invasive cancer other than ovarian cancer within 2 years (except basal or squamous
             cell carcinoma of the skin that has been definitely treated)

          -  Symptomatic uncontrolled brain metastasis

          -  Is pregnant or breast feeding

          -  Immunocompromised patients

          -  Known active hepatic disease

          -  Prior treatment with a known PARP inhibitor
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Studies</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0698</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027-5822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5317</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260-2070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962-1956</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Farmington</city>
        <state>New Mexico</state>
        <zip>87401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001-3788</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203-1625</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Graz</city>
        <zip>A-8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Innsbruck</city>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aalborg</city>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Besançon Cedex</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Brieuc</city>
        <zip>22015 cedex</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint-Herblain cedex</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Strasbourg Cedex</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Wuerttemberg</state>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Goettingen</city>
        <state>Niedersachsen</state>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Duesseldorf</city>
        <state>Nordrhein-Westfalen</state>
        <zip>40217</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hannover</city>
        <zip>30177</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miskolc</city>
        <zip>3501</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Szolnok</city>
        <zip>5004</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kfar-Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tel-Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brescia</city>
        <state>Lombardia</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Monza</city>
        <state>Lombardia</state>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Catania</city>
        <state>Sicilia</state>
        <zip>95126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pisa</city>
        <state>Toscana</state>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aviano (pn)</city>
        <state>Veneto</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>MIlano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oslo</city>
        <zip>0379</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80-219</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80-402</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lodz</city>
        <zip>94-029</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Linköping</city>
        <zip>SE-581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lund</city>
        <zip>SE-221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rhyl</city>
        <state>Flintshire</state>
        <zip>LL18 5UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nottingham</city>
        <state>Nottinghamshire</state>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Yeovil</city>
        <state>Somerset</state>
        <zip>BA21 4AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B18 7QH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bebington, Wirral</city>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SW36JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>WC1E 6DB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Maidstone</city>
        <zip>ME16 9QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taunton</city>
        <zip>TA1 5DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.facingourrisk.org</url>
    <description>Facing our risk of cancer empowered website</description>
  </link>
  <reference>
    <citation>Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Mądry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA; ENGOT-OV16/NOVA Investigators. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016 Dec 1;375(22):2154-2164. Epub 2016 Oct 7.</citation>
    <PMID>27717299</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 11, 2013</study_first_submitted>
  <study_first_submitted_qc>May 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2013</study_first_posted>
  <results_first_submitted>October 18, 2018</results_first_submitted>
  <results_first_submitted_qc>April 10, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 1, 2019</results_first_posted>
  <last_update_submitted>May 27, 2020</last_update_submitted>
  <last_update_submitted_qc>May 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ovarian cancer</keyword>
  <keyword>platinum sensitive</keyword>
  <keyword>gBRCAmut</keyword>
  <keyword>BRCA</keyword>
  <keyword>high-grade serous histology</keyword>
  <keyword>PARP inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niraparib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First patient enrolled 26Aug 2013. Study is ongoing; Data cutoff date of 30May2016 There were 7 patients who were randomized, but did not receive treatment (2 in gBRCA Niraparib; 3 in Non-gBRCA Niraparib and 2 in Non-gBRCA Placebo groups).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>gBRCA Niraparib</title>
          <description>Niraparib (300 mg) once daily in 28-day cycles until disease progression in patients with germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
        </group>
        <group group_id="P2">
          <title>gBRCA Placebo</title>
          <description>Placebo once daily in 28-day cycles until disease progression in patients with germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
        </group>
        <group group_id="P3">
          <title>Non-gBRCA Niraparib</title>
          <description>Niraparib (300 mg) once daily in 28-day cycles until disease progression in patients without germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
        </group>
        <group group_id="P4">
          <title>Non-gBRCA Placebo</title>
          <description>Placebo once daily in 28-day cycles until disease progression in patients without germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="138"/>
                <participants group_id="P2" count="65"/>
                <participants group_id="P3" count="234"/>
                <participants group_id="P4" count="116"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="46"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="61"/>
                <participants group_id="P3" count="188"/>
                <participants group_id="P4" count="104"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="33"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="129"/>
                <participants group_id="P4" count="98"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment Associated Risk</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reasons</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non Compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The baseline analysis population was the intent-to-treat population, defined as all randomized patients with patients analyzed according to the study drug assigned via randomization.</population>
      <group_list>
        <group group_id="B1">
          <title>gBRCA Niraparib</title>
          <description>Niraparib (300 mg) once daily in 28-day cycles until disease progression in patients with germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
        </group>
        <group group_id="B2">
          <title>gBRCA Placebo</title>
          <description>Placebo once daily in 28-day cycles until disease progression in patients with germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
        </group>
        <group group_id="B3">
          <title>Non-gBRCA Niraparib</title>
          <description>Niraparib (300 mg) once daily in 28-day cycles until disease progression in patients without germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
        </group>
        <group group_id="B4">
          <title>Non- gBRCA Placebo</title>
          <description>Placebo once daily in 28-day cycles until disease progression in patients without germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="138"/>
            <count group_id="B2" value="65"/>
            <count group_id="B3" value="234"/>
            <count group_id="B4" value="116"/>
            <count group_id="B5" value="553"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="130"/>
                    <measurement group_id="B4" value="69"/>
                    <measurement group_id="B5" value="358"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="104"/>
                    <measurement group_id="B4" value="47"/>
                    <measurement group_id="B5" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.9" spread="9.25"/>
                    <measurement group_id="B2" value="57.2" spread="9.24"/>
                    <measurement group_id="B3" value="62.3" spread="9.25"/>
                    <measurement group_id="B4" value="61.3" spread="9.52"/>
                    <measurement group_id="B5" value="60.1" spread="9.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="234"/>
                    <measurement group_id="B4" value="116"/>
                    <measurement group_id="B5" value="553"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="202"/>
                    <measurement group_id="B4" value="99"/>
                    <measurement group_id="B5" value="479"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="201"/>
                    <measurement group_id="B4" value="101"/>
                    <measurement group_id="B5" value="480"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Data on multiple race categories not collected</measurement>
                    <measurement group_id="B2" value="NA">Data on multiple race categories not collected</measurement>
                    <measurement group_id="B3" value="NA">Data on multiple race categories not collected</measurement>
                    <measurement group_id="B4" value="NA">Data on multiple race categories not collected</measurement>
                    <measurement group_id="B5" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time to Progression on Penultimate Platinum Therapy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>6 to&lt;12 mo</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="90"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B5" value="214"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=12 mo</title>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="144"/>
                    <measurement group_id="B4" value="72"/>
                    <measurement group_id="B5" value="339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Best response on Last Platinum Therapy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Complete response</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="117"/>
                    <measurement group_id="B4" value="60"/>
                    <measurement group_id="B5" value="281"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial response</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="117"/>
                    <measurement group_id="B4" value="56"/>
                    <measurement group_id="B5" value="272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Use of Bevacizumab with the penultimate or last platinum regimen</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="142"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="172"/>
                    <measurement group_id="B4" value="86"/>
                    <measurement group_id="B5" value="411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Lines of Chemotherapy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="155"/>
                    <measurement group_id="B4" value="77"/>
                    <measurement group_id="B5" value="332"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="79"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="219"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-Free Survival (PFS) in Cohort With Germline BRCA Mutation (gBRCA)</title>
        <description>PFS was defined as the time between randomization and disease progression or death from any cause. Computed tomography or magnetic resonance imaging to assess disease progression was performed at baseline, every 8 weeks through cycle 14, and then every 12 weeks until treatment discontinuation. The objective assessment of disease progression was determined by means of central radiologic and clinical review, according to Response Evaluation Criteria in Solid Tumors (RECIST),version 1.1, which was performed in a blinded fashion.</description>
        <time_frame>From date of randomization to the earliest date of disease progression or death from any cause.</time_frame>
        <population>Intent-to-treat (ITT) population defined as all randomized patients with patients analyzed according to the study drug assigned via randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>gBRCA Niraparib</title>
            <description>Niraparib (300 mg) once daily in 28-day cycles until disease progression in patients with germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
          <group group_id="O2">
            <title>gBRCA Placebo</title>
            <description>Placebo once daily in 28-day cycles until disease progression in patients with germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (PFS) in Cohort With Germline BRCA Mutation (gBRCA)</title>
          <description>PFS was defined as the time between randomization and disease progression or death from any cause. Computed tomography or magnetic resonance imaging to assess disease progression was performed at baseline, every 8 weeks through cycle 14, and then every 12 weeks until treatment discontinuation. The objective assessment of disease progression was determined by means of central radiologic and clinical review, according to Response Evaluation Criteria in Solid Tumors (RECIST),version 1.1, which was performed in a blinded fashion.</description>
          <population>Intent-to-treat (ITT) population defined as all randomized patients with patients analyzed according to the study drug assigned via randomization.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="12.9" upper_limit="NA">Upper limit of confidence interval (CI) was not estimable as upper limits of CI for survivor function were above 0.5 (SAS PROC LIFETEST).</measurement>
                    <measurement group_id="O2" value="5.5" lower_limit="3.8" upper_limit="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Two-sided P-value. PFS was independently evaluated in gBRCAmut cohort and non-gBRCAmut cohort.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>Strata: tm to progression after penultimate platinum tx; use of bevacizumab w/penultimate or last platinum tx; best response during last platinum tx.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.173</ci_lower_limit>
            <ci_upper_limit>0.410</ci_upper_limit>
            <estimate_desc>Niraparib:Placebo, based on the stratified Cox Proportional Hazards Model using randomization stratification factors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progression-Free Survival (PFS) in Cohort With No Germline BCRA With Homologous Recombination Deficiency-positive (HRD+) Tumors (Non-gBRCAmut HRD+)</title>
        <description>PFS was defined as the time between randomization and disease progression or death from any cause. Computed tomography or magnetic resonance imaging to assess disease progression was performed at baseline, every 8 weeks through cycle 14, and then every 12 weeks until treatment discontinuation. The objective assessment of disease progression was determined by means of central radiologic and clinical review, according to Response Evaluation Criteria in Solid Tumors (RECIST),version 1.1, which was performed in a blinded fashion.</description>
        <time_frame>From date of randomization to the earliest date of disease progression or death from any cause</time_frame>
        <population>Intent-to-treat (ITT) population defined as all randomized patients with patients analyzed according to the study drug assigned via randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-gBRCAmut HRD+ Niraparib</title>
            <description>Niraparib (300 mg) once daily in 28-day cycles until disease progression in patients with homologous recombination deficiency-positive (HRD+) tumors Niraparib vs. Placebo 2:1 ratio</description>
          </group>
          <group group_id="O2">
            <title>Non-gBRCAmut HRD+ Placebo</title>
            <description>Placebo once daily in 28-day cycles until disease progression patients with homologous recombination deficiency-positive (HRD+) tumors Niraparib vs. Placebo 2:1 ratio</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (PFS) in Cohort With No Germline BCRA With Homologous Recombination Deficiency-positive (HRD+) Tumors (Non-gBRCAmut HRD+)</title>
          <description>PFS was defined as the time between randomization and disease progression or death from any cause. Computed tomography or magnetic resonance imaging to assess disease progression was performed at baseline, every 8 weeks through cycle 14, and then every 12 weeks until treatment discontinuation. The objective assessment of disease progression was determined by means of central radiologic and clinical review, according to Response Evaluation Criteria in Solid Tumors (RECIST),version 1.1, which was performed in a blinded fashion.</description>
          <population>Intent-to-treat (ITT) population defined as all randomized patients with patients analyzed according to the study drug assigned via randomization.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" lower_limit="8.1" upper_limit="15.9"/>
                    <measurement group_id="O2" value="3.8" lower_limit="3.5" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Two-sided P-value. PFS was independently evaluated in gBRCAmut cohort and non-gBRCAmut cohort. Hierarchical testing: HRD+ subset tested first. If HRD+ subset demonstrated statistical significance, overall non-gBRCA cohort was then tested</p_value_desc>
            <method>Log Rank</method>
            <method_desc>Strata: tm to progression after penultimate platinum tx; use of bevacizumab w/penultimate or last platinum tx; best response during last platinum tx.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.243</ci_lower_limit>
            <ci_upper_limit>0.586</ci_upper_limit>
            <estimate_desc>Niraparib:Placebo, based on the stratified Cox Proportional Hazards Model using randomization stratification factors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progression-Free Survival (PFS) in Cohort With No Germline BRCA Mutation (Non-gBRCA)</title>
        <description>PFS was defined as the time between randomization and disease progression or death from any cause. Computed tomography or magnetic resonance imaging to assess disease progression was performed at baseline, every 8 weeks through cycle 14, and then every 12 weeks until treatment discontinuation. The objective assessment of disease progression was determined by means of central radiologic and clinical review, according to Response Evaluation Criteria in Solid Tumors (RECIST),version 1.1, which was performed in a blinded fashion.</description>
        <time_frame>From date of randomization to the earliest date of disease progression or death from any cause.</time_frame>
        <population>Intent-to-treat (ITT) population defined as all randomized patients with patients analyzed according to the study drug assigned via randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-gBRCA Niraparib</title>
            <description>Niraparib (300 mg) once daily in 28-day cycles until disease progression in patients without germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
          <group group_id="O2">
            <title>Non-gBRCA Placebo</title>
            <description>Placebo once daily in 28-day cycles until disease progression in patients without germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (PFS) in Cohort With No Germline BRCA Mutation (Non-gBRCA)</title>
          <description>PFS was defined as the time between randomization and disease progression or death from any cause. Computed tomography or magnetic resonance imaging to assess disease progression was performed at baseline, every 8 weeks through cycle 14, and then every 12 weeks until treatment discontinuation. The objective assessment of disease progression was determined by means of central radiologic and clinical review, according to Response Evaluation Criteria in Solid Tumors (RECIST),version 1.1, which was performed in a blinded fashion.</description>
          <population>Intent-to-treat (ITT) population defined as all randomized patients with patients analyzed according to the study drug assigned via randomization.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="234"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" lower_limit="7.2" upper_limit="11.2"/>
                    <measurement group_id="O2" value="3.9" lower_limit="3.7" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Two-sided P-value. PFS was independently evaluated in gBRCAmut cohort and non-gBRCAmut cohort. Hierarchical testing: HRD+ subset tested first. If HRD+ subset demonstrated statistical significance, overall non-gBRCA cohort was then tested.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>Strata: tm to progression after penultimate platinum tx; use of bevacizumab w/penultimate or last platinum tx; best response during last platinum tx.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.338</ci_lower_limit>
            <ci_upper_limit>0.607</ci_upper_limit>
            <estimate_desc>Niraparib:Placebo, based on the stratified Cox Proportional Hazards Model using randomization stratification factors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Subsequent Therapy (TFST) in Cohort With Germline BRCA Mutation (gBRCA)</title>
        <description>Patients were to be followed off treatment every 3 months for subsequent anti-cancer treatment. The TFST was defined as the time from the date of randomization to the start date of the first subsequent anti-cancer therapy or death.</description>
        <time_frame>From date of randomization to the earliest date of first subsequent therapy or death.</time_frame>
        <population>Intent-to-treat (ITT) population defined as all randomized patients with patients analyzed according to the study drug assigned via randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>gBRCA Niraparib</title>
            <description>Niraparib (300 mg) once daily in 28-day cycles until disease progression in patients with germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
          <group group_id="O2">
            <title>gBRCA Placebo</title>
            <description>Placebo once daily in 28-day cycles until disease progression in patients with germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Subsequent Therapy (TFST) in Cohort With Germline BRCA Mutation (gBRCA)</title>
          <description>Patients were to be followed off treatment every 3 months for subsequent anti-cancer treatment. The TFST was defined as the time from the date of randomization to the start date of the first subsequent anti-cancer therapy or death.</description>
          <population>Intent-to-treat (ITT) population defined as all randomized patients with patients analyzed according to the study drug assigned via randomization.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.0" lower_limit="17.5" upper_limit="NA">Upper limit of confidence interval (CI) was not estimable as upper limits of CI for survivor function were above 0.5 (SAS PROC LIFETEST).</measurement>
                    <measurement group_id="O2" value="8.4" lower_limit="6.6" upper_limit="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Two-sided P-value.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>Strata: tm to progression after penultimate platinum tx; use of bevacizumab w/penultimate or last platinum tx; best response during last platinum tx.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.205</ci_lower_limit>
            <ci_upper_limit>0.481</ci_upper_limit>
            <estimate_desc>Niraparib:Placebo, based on the stratified Cox Proportional Hazards Model using randomization stratification factors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Subsequent Therapy (TFST) in Cohort With No Germline BRCA Mutation (Non-gBRCA)</title>
        <description>Patients were to be followed off treatment every 3 months for subsequent anti-cancer treatment. The TFST was defined as the time from the date of randomization to the start date of the first subsequent anti-cancer therapy or death.</description>
        <time_frame>From date of randomization to the earliest date of first subsequent therapy or death.</time_frame>
        <population>Intent-to-treat (ITT) population defined as all randomized patients with patients analyzed according to the study drug assigned via randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-gBRCA Niraparib</title>
            <description>Niraparib (300 mg) once daily in 28-day cycles until disease progression in patients without germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
          <group group_id="O2">
            <title>Non-gBRCA Placebo</title>
            <description>Placebo once daily in 28-day cycles until disease progression in patients without germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Subsequent Therapy (TFST) in Cohort With No Germline BRCA Mutation (Non-gBRCA)</title>
          <description>Patients were to be followed off treatment every 3 months for subsequent anti-cancer treatment. The TFST was defined as the time from the date of randomization to the start date of the first subsequent anti-cancer therapy or death.</description>
          <population>Intent-to-treat (ITT) population defined as all randomized patients with patients analyzed according to the study drug assigned via randomization.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="234"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" lower_limit="9.7" upper_limit="13.1"/>
                    <measurement group_id="O2" value="7.2" lower_limit="5.7" upper_limit="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Two-sided P-value.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>Strata: tm to progression after penultimate platinum tx; use of bevacizumab w/penultimate or last platinum tx; best response during last platinum tx.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.412</ci_lower_limit>
            <ci_upper_limit>0.721</ci_upper_limit>
            <estimate_desc>Niraparib:Placebo, based on the stratified Cox Proportional Hazards Model using randomization stratification factors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chemotherapy-Free Interval (CFI) in Cohort With Germline BRCA Mutation (gBRCA)</title>
        <description>CFI was defined as the time from the last platinum therapy prior to randomization to the initiation of the next anti-cancer therapy after maintenance treatment.</description>
        <time_frame>From date of last platinum therapy prior to randomization to the initiation of the next anti-cancer therapy after maintenance treatment.</time_frame>
        <population>Intent-to-treat (ITT) population defined as all randomized patients with patients analyzed according to the study drug assigned via randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>gBRCA Niraparib</title>
            <description>Niraparib (300 mg) once daily in 28-day cycles until disease progression in patients with germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
          <group group_id="O2">
            <title>gBRCA Placebo</title>
            <description>Placebo once daily in 28-day cycles until disease progression in patients with germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
        </group_list>
        <measure>
          <title>Chemotherapy-Free Interval (CFI) in Cohort With Germline BRCA Mutation (gBRCA)</title>
          <description>CFI was defined as the time from the last platinum therapy prior to randomization to the initiation of the next anti-cancer therapy after maintenance treatment.</description>
          <population>Intent-to-treat (ITT) population defined as all randomized patients with patients analyzed according to the study drug assigned via randomization.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.8" lower_limit="17.9" upper_limit="NA">Upper limit of confidence interval (CI) was not estimable as upper limits of CI for survivor function were above 0.5 (SAS PROC LIFETEST).</measurement>
                    <measurement group_id="O2" value="9.4" lower_limit="7.9" upper_limit="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Two-sided P-value.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>Strata: tm to progression after penultimate platinum tx; use of bevacizumab w/penultimate or last platinum tx; best response during last platinum tx.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.166</ci_lower_limit>
            <ci_upper_limit>0.409</ci_upper_limit>
            <estimate_desc>Niraparib:Placebo, based on the stratified Cox Proportional Hazards Model using randomization stratification factors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chemotherapy-Free Interval (CFI) in Cohort With No Germline BRCA Mutation (Non-gBRCA)</title>
        <description>CFI was defined as the time from the last platinum therapy prior to randomization to the initiation of the next anti-cancer therapy after maintenance treatment.</description>
        <time_frame>From date of last platinum therapy prior to randomization to the initiation of the next anti-cancer therapy after maintenance treatment.</time_frame>
        <population>Intent-to-treat (ITT) population defined as all randomized patients with patients analyzed according to the study drug assigned via randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-gBRCA Niraparib</title>
            <description>Niraparib (300 mg) once daily in 28-day cycles until disease progression in patients without germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
          <group group_id="O2">
            <title>Non-gBRCA Placebo</title>
            <description>Placebo once daily in 28-day cycles until disease progression in patients without germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
        </group_list>
        <measure>
          <title>Chemotherapy-Free Interval (CFI) in Cohort With No Germline BRCA Mutation (Non-gBRCA)</title>
          <description>CFI was defined as the time from the last platinum therapy prior to randomization to the initiation of the next anti-cancer therapy after maintenance treatment.</description>
          <population>Intent-to-treat (ITT) population defined as all randomized patients with patients analyzed according to the study drug assigned via randomization.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="234"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" lower_limit="11.0" upper_limit="14.7"/>
                    <measurement group_id="O2" value="8.6" lower_limit="6.9" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Two-sided P-value.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>Strata: tm to progression after penultimate platinum tx; use of bevacizumab w/penultimate or last platinum tx; best response during last platinum tx.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.370</ci_lower_limit>
            <ci_upper_limit>0.666</ci_upper_limit>
            <estimate_desc>Niraparib:Placebo, based on the stratified Cox Proportional Hazards Model using randomization stratification factors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-Free Survival 2 (PFS2) in Cohort With Germline BRCA Mutation (gBRCA)</title>
        <description>Patients were to be followed off treatment every 3 months for subsequent anti-cancer treatment, including outcome of such therapy, any new malignancies, and survival status. PFS2 was defined as the time from treatment randomization to the earlier of the date of disease progression on the next anti-cancer therapy following study treatment or death due to any cause. This study is ongoing, PFS2 is immature at this stage of primary analysis.</description>
        <time_frame>From treatment randomization to the earlier of the date of disease progression on the next anti-cancer therapy following study treatment or death due to any cause.</time_frame>
        <population>Intent-to-treat (ITT) population defined as all randomized patients with patients analyzed according to the study drug assigned via randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>gBRCA Niraparib</title>
            <description>Niraparib (300 mg) once daily in 28-day cycles until disease progression in patients with germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
          <group group_id="O2">
            <title>gBRCA Placebo</title>
            <description>Placebo once daily in 28-day cycles until disease progression in patients with germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival 2 (PFS2) in Cohort With Germline BRCA Mutation (gBRCA)</title>
          <description>Patients were to be followed off treatment every 3 months for subsequent anti-cancer treatment, including outcome of such therapy, any new malignancies, and survival status. PFS2 was defined as the time from treatment randomization to the earlier of the date of disease progression on the next anti-cancer therapy following study treatment or death due to any cause. This study is ongoing, PFS2 is immature at this stage of primary analysis.</description>
          <population>Intent-to-treat (ITT) population defined as all randomized patients with patients analyzed according to the study drug assigned via randomization.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.8" lower_limit="20.3" upper_limit="NA">Upper limit of confidence interval (CI) was not estimable as upper limits of CI for survivor function were above 0.5 (SAS PROC LIFETEST).</measurement>
                    <measurement group_id="O2" value="19.5" lower_limit="13.3" upper_limit="NA">Upper limit of confidence interval (CI) was not estimable as upper limits of CI for survivor function were above 0.5 (SAS PROC LIFETEST).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0062</p_value>
            <p_value_desc>Two-sided P-value.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>Strata: tm to progression after penultimate platinum tx; use of bevacizumab w/penultimate or last platinum tx; best response during last platinum tx.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.280</ci_lower_limit>
            <ci_upper_limit>0.821</ci_upper_limit>
            <estimate_desc>Niraparib:Placebo, based on the stratified Cox Proportional Hazards Model using randomization stratification factors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-Free Survival 2 (PFS2) in Cohort With No Germline BRCA Mutation (Non-gBRCA)</title>
        <description>Patients were to be followed off treatment every 3 months for subsequent anti-cancer treatment, including outcome of such therapy, any new malignancies, and survival status. PFS2 was defined as the time from treatment randomization to the earlier of the date of disease progression on the next anti-cancer therapy following study treatment or death due to any cause. This study is ongoing, PFS2 is immature at this stage of primary analysis.</description>
        <time_frame>From treatment randomization to the earlier of the date of disease progression on the next anti-cancer therapy following study treatment or death due to any cause.</time_frame>
        <population>Intent-to-treat (ITT) population defined as all randomized patients with patients analyzed according to the study drug assigned via randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-gBRCA Niraparib</title>
            <description>Niraparib (300 mg) once daily in 28-day cycles until disease progression in patients without germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
          <group group_id="O2">
            <title>Non-gBRCA Placebo</title>
            <description>Placebo once daily in 28-day cycles until disease progression in patients without germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival 2 (PFS2) in Cohort With No Germline BRCA Mutation (Non-gBRCA)</title>
          <description>Patients were to be followed off treatment every 3 months for subsequent anti-cancer treatment, including outcome of such therapy, any new malignancies, and survival status. PFS2 was defined as the time from treatment randomization to the earlier of the date of disease progression on the next anti-cancer therapy following study treatment or death due to any cause. This study is ongoing, PFS2 is immature at this stage of primary analysis.</description>
          <population>Intent-to-treat (ITT) population defined as all randomized patients with patients analyzed according to the study drug assigned via randomization.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="234"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6" lower_limit="16.2" upper_limit="21.7"/>
                    <measurement group_id="O2" value="15.6" lower_limit="13.2" upper_limit="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0293</p_value>
            <p_value_desc>Two-sided P-value.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>Strata: tm to progression after penultimate platinum tx; use of bevacizumab w/penultimate or last platinum tx; best response during last platinum tx.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.494</ci_lower_limit>
            <ci_upper_limit>0.964</ci_upper_limit>
            <estimate_desc>Niraparib:Placebo, based on the stratified Cox Proportional Hazards Model using randomization stratification factors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) in Cohort With Germline BRCA Mutation (gBRCA)</title>
        <description>Patients were to be followed off treatment every 3 months for survival status. Overall survival is defined as the date of randomization to the date of death by any cause. Results not yet reported.</description>
        <time_frame>From treatment randomization to date of death by any cause</time_frame>
        <posting_date>2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) in Cohort With No Germline BRCA Mutation (Non-gBRCA)</title>
        <description>Patients were to be followed off treatment every 3 months for survival status. Overall survival is defined as the date of randomization to the date of death by any cause. Results not yet reported.</description>
        <time_frame>From treatment randomization to date of death by any cause</time_frame>
        <posting_date>2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Second Subsequent Therapy (TSST) in Cohort With Germline BRCA Mutation (gBRCA)</title>
        <description>Patients were to be followed off treatment every 3 months for subsequent anti-cancer treatment, including outcome of such therapy, any new malignancies, and survival status. TSST is defined as the date of randomization to the earlier of the start date of second follow-up anti-cancer treatment or death. Results not yet reported.</description>
        <time_frame>From the date of randomization to the start date of the second subsequent anti-cancer therapy.</time_frame>
        <posting_date>2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Second Subsequent Therapy (TSST) in Cohort With No Germline BRCA Mutation (Non-gBRCA)</title>
        <description>Patients were to be followed off treatment every 3 months for subsequent anti-cancer treatment, including outcome of such therapy, any new malignancies, and survival status. TSST is defined as the date of randomization to the earlier of the start date of second follow-up anti-cancer treatment or death. Results not yet reported.</description>
        <time_frame>From the date of randomization to the start date of the second subsequent anti-cancer therapy.</time_frame>
        <posting_date>2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) in Cohort With Germline BRCA</title>
        <description>The FOSI is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Patients respond to their symptom experience over the past 7 days using a 5-point Likert scale. The total symptom index is calculated as the total of the 8 scores, ranging from 0 (&quot;severely symptomatic&quot;) to 32 (&quot;asymptomatic&quot;). A positive change from baseline indicates improvement.</description>
        <time_frame>At Cycle 2</time_frame>
        <population>Intent-to-treat population (all randomized patients with patients analyzed to the study drug assigned) with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>gBRCA Niraparib</title>
            <description>Niraparib (300 mg) once daily in 28-day cycles until disease progression in patients with germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
          <group group_id="O2">
            <title>gBRCA Placebo</title>
            <description>Placebo once daily in 28-day cycles until disease progression in patients with germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) in Cohort With Germline BRCA</title>
          <description>The FOSI is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Patients respond to their symptom experience over the past 7 days using a 5-point Likert scale. The total symptom index is calculated as the total of the 8 scores, ranging from 0 (&quot;severely symptomatic&quot;) to 32 (&quot;asymptomatic&quot;). A positive change from baseline indicates improvement.</description>
          <population>Intent-to-treat population (all randomized patients with patients analyzed to the study drug assigned) with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="4.58"/>
                    <measurement group_id="O2" value="-0.3" spread="3.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) in Cohort With Germline BRCA</title>
        <description>The FOSI is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Patients respond to their symptom experience over the past 7 days using a 5-point Likert scale. The total symptom index is calculated as the total of the 8 scores, ranging from 0 (&quot;severely symptomatic&quot;) to 32 (&quot;asymptomatic&quot;). A positive change from baseline indicates improvement.</description>
        <time_frame>At Cycle 4</time_frame>
        <population>Intent-to-treat population (all randomized patients with patients analyzed according to the study drug assigned) with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>gBRCA Niraparib</title>
            <description>Niraparib (300 mg) once daily in 28-day cycles until disease progression in patients with germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
          <group group_id="O2">
            <title>gBRCA Placebo</title>
            <description>Placebo once daily in 28-day cycles until disease progression in patients with germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) in Cohort With Germline BRCA</title>
          <description>The FOSI is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Patients respond to their symptom experience over the past 7 days using a 5-point Likert scale. The total symptom index is calculated as the total of the 8 scores, ranging from 0 (&quot;severely symptomatic&quot;) to 32 (&quot;asymptomatic&quot;). A positive change from baseline indicates improvement.</description>
          <population>Intent-to-treat population (all randomized patients with patients analyzed according to the study drug assigned) with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="4.07"/>
                    <measurement group_id="O2" value="-0.3" spread="3.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) in Cohort With Germline BRCA</title>
        <description>The FOSI is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Patients respond to their symptom experience over the past 7 days using a 5-point Likert scale. The total symptom index is calculated as the total of the 8 scores, ranging from 0 (&quot;severely symptomatic&quot;) to 32 (&quot;asymptomatic&quot;). A positive change from baseline indicates improvement.</description>
        <time_frame>At Cycle 6</time_frame>
        <population>Intent-to-treat population (all randomized patients with patients analyzed according to the study drug assigned) with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>gBRCA Niraparib</title>
            <description>Niraparib (300 mg) once daily in 28-day cycles until disease progression in patients with germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
          <group group_id="O2">
            <title>gBRCA Placebo</title>
            <description>Placebo once daily in 28-day cycles until disease progression in patients with germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) in Cohort With Germline BRCA</title>
          <description>The FOSI is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Patients respond to their symptom experience over the past 7 days using a 5-point Likert scale. The total symptom index is calculated as the total of the 8 scores, ranging from 0 (&quot;severely symptomatic&quot;) to 32 (&quot;asymptomatic&quot;). A positive change from baseline indicates improvement.</description>
          <population>Intent-to-treat population (all randomized patients with patients analyzed according to the study drug assigned) with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="3.77"/>
                    <measurement group_id="O2" value="-0.5" spread="4.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) in Cohort With Germline BRCA</title>
        <description>The FOSI is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Patients respond to their symptom experience over the past 7 days using a 5-point Likert scale. The total symptom index is calculated as the total of the 8 scores, ranging from 0 (&quot;severely symptomatic&quot;) to 32 (&quot;asymptomatic&quot;). A positive change from baseline indicates improvement.</description>
        <time_frame>At Post Progression</time_frame>
        <population>Intent-to-treat population (all randomized patients with patients analyzed according to the study drug assigned) with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>gBRCA Niraparib</title>
            <description>Niraparib (300 mg) once daily in 28-day cycles until disease progression in patients with germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
          <group group_id="O2">
            <title>gBRCA Placebo</title>
            <description>Placebo once daily in 28-day cycles until disease progression in patients with germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) in Cohort With Germline BRCA</title>
          <description>The FOSI is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Patients respond to their symptom experience over the past 7 days using a 5-point Likert scale. The total symptom index is calculated as the total of the 8 scores, ranging from 0 (&quot;severely symptomatic&quot;) to 32 (&quot;asymptomatic&quot;). A positive change from baseline indicates improvement.</description>
          <population>Intent-to-treat population (all randomized patients with patients analyzed according to the study drug assigned) with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="4.36"/>
                    <measurement group_id="O2" value="-1.2" spread="4.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) in Cohort With no Germline BRCA</title>
        <description>The FOSI is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Patients respond to their symptom experience over the past 7 days using a 5-point Likert scale. The total symptom index is calculated as the total of the 8 scores, ranging from 0 (&quot;severely symptomatic&quot;) to 32 (&quot;asymptomatic&quot;). A positive change from baseline indicates improvement.</description>
        <time_frame>At Cycle 2</time_frame>
        <population>Intent-to-treat population (all randomized patients with patients analyzed according to the study drug assigned) with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-gBRCA Niraparib</title>
            <description>Niraparib (300 mg) once daily in 28-day cycles until disease progression in patients without germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
          <group group_id="O2">
            <title>Non-gBRCA Placebo</title>
            <description>Placebo once daily in 28-day cycles until disease progression in patients without germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) in Cohort With no Germline BRCA</title>
          <description>The FOSI is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Patients respond to their symptom experience over the past 7 days using a 5-point Likert scale. The total symptom index is calculated as the total of the 8 scores, ranging from 0 (&quot;severely symptomatic&quot;) to 32 (&quot;asymptomatic&quot;). A positive change from baseline indicates improvement.</description>
          <population>Intent-to-treat population (all randomized patients with patients analyzed according to the study drug assigned) with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="3.78"/>
                    <measurement group_id="O2" value="-0.3" spread="2.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) in Cohort With no Germline BRCA</title>
        <description>The FOSI is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Patients respond to their symptom experience over the past 7 days using a 5-point Likert scale. The total symptom index is calculated as the total of the 8 scores, ranging from 0 (&quot;severely symptomatic&quot;) to 32 (&quot;asymptomatic&quot;). A positive change from baseline indicates improvement.</description>
        <time_frame>At Cycle 4</time_frame>
        <population>Intent-to-treat population (all randomized patients with patients analyzed according to the study drug assigned) with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-gBRCA Niraparib</title>
            <description>Niraparib (300 mg) once daily in 28-day cycles until disease progression in patients without germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
          <group group_id="O2">
            <title>Non-gBRCA Placebo</title>
            <description>Placebo once daily in 28-day cycles until disease progression in patients without germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) in Cohort With no Germline BRCA</title>
          <description>The FOSI is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Patients respond to their symptom experience over the past 7 days using a 5-point Likert scale. The total symptom index is calculated as the total of the 8 scores, ranging from 0 (&quot;severely symptomatic&quot;) to 32 (&quot;asymptomatic&quot;). A positive change from baseline indicates improvement.</description>
          <population>Intent-to-treat population (all randomized patients with patients analyzed according to the study drug assigned) with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="4.16"/>
                    <measurement group_id="O2" value="-0.9" spread="4.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) in Cohort With no Germline BRCA</title>
        <description>The FOSI is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Patients respond to their symptom experience over the past 7 days using a 5-point Likert scale. The total symptom index is calculated as the total of the 8 scores, ranging from 0 (&quot;severely symptomatic&quot;) to 32 (&quot;asymptomatic&quot;). A positive change from baseline indicates improvement.</description>
        <time_frame>At Cycle 6</time_frame>
        <population>Intent-to-treat population (all randomized patients with patients analyzed according to the study drug assigned) with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-gBRCA Niraparib</title>
            <description>Niraparib (300 mg) once daily in 28-day cycles until disease progression in patients without germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
          <group group_id="O2">
            <title>Non-gBRCA Placebo</title>
            <description>Placebo once daily in 28-day cycles until disease progression in patients without germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) in Cohort With no Germline BRCA</title>
          <description>The FOSI is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Patients respond to their symptom experience over the past 7 days using a 5-point Likert scale. The total symptom index is calculated as the total of the 8 scores, ranging from 0 (&quot;severely symptomatic&quot;) to 32 (&quot;asymptomatic&quot;). A positive change from baseline indicates improvement.</description>
          <population>Intent-to-treat population (all randomized patients with patients analyzed according to the study drug assigned) with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="3.76"/>
                    <measurement group_id="O2" value="-0.9" spread="3.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) in Cohort With no Germline BRCA</title>
        <description>The FOSI is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Patients respond to their symptom experience over the past 7 days using a 5-point Likert scale. The total symptom index is calculated as the total of the 8 scores, ranging from 0 (&quot;severely symptomatic&quot;) to 32 (&quot;asymptomatic&quot;). A positive change from baseline indicates improvement.</description>
        <time_frame>At Post Progression</time_frame>
        <population>Intent-to-treat population (all randomized patients with patients analyzed according to the study drug assigned) with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-gBRCA Niraparib</title>
            <description>Niraparib (300 mg) once daily in 28-day cycles until disease progression in patients without germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
          <group group_id="O2">
            <title>Non-gBRCA Placebo</title>
            <description>Placebo once daily in 28-day cycles until disease progression in patients without germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) in Cohort With no Germline BRCA</title>
          <description>The FOSI is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Patients respond to their symptom experience over the past 7 days using a 5-point Likert scale. The total symptom index is calculated as the total of the 8 scores, ranging from 0 (&quot;severely symptomatic&quot;) to 32 (&quot;asymptomatic&quot;). A positive change from baseline indicates improvement.</description>
          <population>Intent-to-treat population (all randomized patients with patients analyzed according to the study drug assigned) with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="5.81"/>
                    <measurement group_id="O2" value="-1.8" spread="4.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in EQ-5D-5L in Cohort With Germline BRCA</title>
        <description>EQ-5D-5L is a well-validated, general preference-based, health-related QoL instrument. The EQ-5D-5L encompasses 5 domains, asking patients to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: &quot;no problems&quot; (Level 1), &quot;slight problems&quot; (Level 2), &quot;moderate problems&quot; (Level 3), &quot;severe problems&quot; (Level 4), and &quot;extreme problems&quot; (Level 5). Each domain is assigned a level, and levels are combined to create a 5-digit number describing the patient's health state. For each patient, an index value is determined from a published country-specific value set. This index value or utility score ranges from 0 to 1.00 (with 1.0 representing perfect health) and is used in the calculation of quality-adjusted life years (QALYs) that are used to inform economic valuations of health interventions. A positive change from baseline indicates improvement.</description>
        <time_frame>At Cycle 2</time_frame>
        <population>Intent-to-treat population (all randomized patients with patients analyzed according to the study drug assigned) with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>gBRCA Niraparib</title>
            <description>Niraparib (300 mg) once daily in 28-day cycles until disease progression in patients with germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
          <group group_id="O2">
            <title>gBRCA Placebo</title>
            <description>Placebo once daily in 28-day cycles until disease progression in patients with germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in EQ-5D-5L in Cohort With Germline BRCA</title>
          <description>EQ-5D-5L is a well-validated, general preference-based, health-related QoL instrument. The EQ-5D-5L encompasses 5 domains, asking patients to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: &quot;no problems&quot; (Level 1), &quot;slight problems&quot; (Level 2), &quot;moderate problems&quot; (Level 3), &quot;severe problems&quot; (Level 4), and &quot;extreme problems&quot; (Level 5). Each domain is assigned a level, and levels are combined to create a 5-digit number describing the patient's health state. For each patient, an index value is determined from a published country-specific value set. This index value or utility score ranges from 0 to 1.00 (with 1.0 representing perfect health) and is used in the calculation of quality-adjusted life years (QALYs) that are used to inform economic valuations of health interventions. A positive change from baseline indicates improvement.</description>
          <population>Intent-to-treat population (all randomized patients with patients analyzed according to the study drug assigned) with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.008" spread="0.1092"/>
                    <measurement group_id="O2" value="-0.008" spread="0.1354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in EQ-5D-5L in Cohort With Germline BRCA</title>
        <description>EQ-5D-5L is a well-validated, general preference-based, health-related QoL instrument. The EQ-5D-5L encompasses 5 domains, asking patients to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: &quot;no problems&quot; (Level 1), &quot;slight problems&quot; (Level 2), &quot;moderate problems&quot; (Level 3), &quot;severe problems&quot; (Level 4), and &quot;extreme problems&quot; (Level 5). Each domain is assigned a level, and levels are combined to create a 5-digit number describing the patient's health state. For each patient, an index value is determined from a published country-specific value set. This index value or utility score ranges from 0 to 1.00 (with 1.0 representing perfect health) and is used in the calculation of quality-adjusted life years (QALYs) that are used to inform economic valuations of health interventions. A positive change from baseline indicates improvement.</description>
        <time_frame>At Cycle 4</time_frame>
        <population>Intent-to-treat population (all randomized patients with patients analyzed according to the study drug assigned) with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>gBRCA Niraparib</title>
            <description>Niraparib (300 mg) once daily in 28-day cycles until disease progression in patients with germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
          <group group_id="O2">
            <title>gBRCA Placebo</title>
            <description>Placebo once daily in 28-day cycles until disease progression in patients with germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in EQ-5D-5L in Cohort With Germline BRCA</title>
          <description>EQ-5D-5L is a well-validated, general preference-based, health-related QoL instrument. The EQ-5D-5L encompasses 5 domains, asking patients to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: &quot;no problems&quot; (Level 1), &quot;slight problems&quot; (Level 2), &quot;moderate problems&quot; (Level 3), &quot;severe problems&quot; (Level 4), and &quot;extreme problems&quot; (Level 5). Each domain is assigned a level, and levels are combined to create a 5-digit number describing the patient's health state. For each patient, an index value is determined from a published country-specific value set. This index value or utility score ranges from 0 to 1.00 (with 1.0 representing perfect health) and is used in the calculation of quality-adjusted life years (QALYs) that are used to inform economic valuations of health interventions. A positive change from baseline indicates improvement.</description>
          <population>Intent-to-treat population (all randomized patients with patients analyzed according to the study drug assigned) with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.010" spread="0.1225"/>
                    <measurement group_id="O2" value="-0.035" spread="0.1156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in EQ-5D-5L in Cohort With Germline BRCA</title>
        <description>EQ-5D-5L is a well-validated, general preference-based, health-related QoL instrument. The EQ-5D-5L encompasses 5 domains, asking patients to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: &quot;no problems&quot; (Level 1), &quot;slight problems&quot; (Level 2), &quot;moderate problems&quot; (Level 3), &quot;severe problems&quot; (Level 4), and &quot;extreme problems&quot; (Level 5). Each domain is assigned a level, and levels are combined to create a 5-digit number describing the patient's health state. For each patient, an index value is determined from a published country-specific value set. This index value or utility score ranges from 0 to 1.00 (with 1.0 representing perfect health) and is used in the calculation of quality-adjusted life years (QALYs) that are used to inform economic valuations of health interventions. A positive change from baseline indicates improvement.</description>
        <time_frame>At Cycle 6</time_frame>
        <population>Intent-to-treat population (all randomized patients with patients analyzed according to the study drug assigned) with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>gBRCA Niraparib</title>
            <description>Niraparib (300 mg) once daily in 28-day cycles until disease progression in patients with germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
          <group group_id="O2">
            <title>gBRCA Placebo</title>
            <description>Placebo once daily in 28-day cycles until disease progression in patients with germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in EQ-5D-5L in Cohort With Germline BRCA</title>
          <description>EQ-5D-5L is a well-validated, general preference-based, health-related QoL instrument. The EQ-5D-5L encompasses 5 domains, asking patients to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: &quot;no problems&quot; (Level 1), &quot;slight problems&quot; (Level 2), &quot;moderate problems&quot; (Level 3), &quot;severe problems&quot; (Level 4), and &quot;extreme problems&quot; (Level 5). Each domain is assigned a level, and levels are combined to create a 5-digit number describing the patient's health state. For each patient, an index value is determined from a published country-specific value set. This index value or utility score ranges from 0 to 1.00 (with 1.0 representing perfect health) and is used in the calculation of quality-adjusted life years (QALYs) that are used to inform economic valuations of health interventions. A positive change from baseline indicates improvement.</description>
          <population>Intent-to-treat population (all randomized patients with patients analyzed according to the study drug assigned) with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.002" spread="0.1119"/>
                    <measurement group_id="O2" value="-0.004" spread="0.1463"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in EQ-5D-5L in Cohort With Germline BRCA</title>
        <description>EQ-5D-5L is a well-validated, general preference-based, health-related QoL instrument. The EQ-5D-5L encompasses 5 domains, asking patients to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: &quot;no problems&quot; (Level 1), &quot;slight problems&quot; (Level 2), &quot;moderate problems&quot; (Level 3), &quot;severe problems&quot; (Level 4), and &quot;extreme problems&quot; (Level 5). Each domain is assigned a level, and levels are combined to create a 5-digit number describing the patient's health state. For each patient, an index value is determined from a published country-specific value set. This index value or utility score ranges from 0 to 1.00 (with 1.0 representing perfect health) and is used in the calculation of quality-adjusted life years (QALYs) that are used to inform economic valuations of health interventions. A positive change from baseline indicates improvement.</description>
        <time_frame>At Post Progression</time_frame>
        <population>Intent-to-treat population (all randomized patients with patients analyzed according to the study drug assigned) with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>gBRCA Niraparib</title>
            <description>Niraparib (300 mg) once daily in 28-day cycles until disease progression in patients with germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
          <group group_id="O2">
            <title>gBRCA Placebo</title>
            <description>Placebo once daily in 28-day cycles until disease progression in patients with germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in EQ-5D-5L in Cohort With Germline BRCA</title>
          <description>EQ-5D-5L is a well-validated, general preference-based, health-related QoL instrument. The EQ-5D-5L encompasses 5 domains, asking patients to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: &quot;no problems&quot; (Level 1), &quot;slight problems&quot; (Level 2), &quot;moderate problems&quot; (Level 3), &quot;severe problems&quot; (Level 4), and &quot;extreme problems&quot; (Level 5). Each domain is assigned a level, and levels are combined to create a 5-digit number describing the patient's health state. For each patient, an index value is determined from a published country-specific value set. This index value or utility score ranges from 0 to 1.00 (with 1.0 representing perfect health) and is used in the calculation of quality-adjusted life years (QALYs) that are used to inform economic valuations of health interventions. A positive change from baseline indicates improvement.</description>
          <population>Intent-to-treat population (all randomized patients with patients analyzed according to the study drug assigned) with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.037" spread="0.1102"/>
                    <measurement group_id="O2" value="-0.014" spread="0.1623"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in EQ-5D-5L in Cohort With no Germline BRCA</title>
        <description>EQ-5D-5L is a well-validated, general preference-based, health-related QoL instrument. The EQ-5D-5L encompasses 5 domains, asking patients to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: &quot;no problems&quot; (Level 1), &quot;slight problems&quot; (Level 2), &quot;moderate problems&quot; (Level 3), &quot;severe problems&quot; (Level 4), and &quot;extreme problems&quot; (Level 5). Each domain is assigned a level, and levels are combined to create a 5-digit number describing the patient's health state. For each patient, an index value is determined from a published country-specific value set. This index value or utility score ranges from 0 to 1.00 (with 1.0 representing perfect health) and is used in the calculation of quality-adjusted life years (QALYs) that are used to inform economic valuations of health interventions. A positive change from baseline indicates improvement.</description>
        <time_frame>At Cycle 2</time_frame>
        <population>Intent-to-treat population (all randomized patients with patients analyzed according to the study drug assigned) with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-gBRCA Niraparib</title>
            <description>Niraparib (300 mg) once daily in 28-day cycles until disease progression in patients without germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
          <group group_id="O2">
            <title>Non-gBRCA Placebo</title>
            <description>Placebo once daily in 28-day cycles until disease progression in patients without germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in EQ-5D-5L in Cohort With no Germline BRCA</title>
          <description>EQ-5D-5L is a well-validated, general preference-based, health-related QoL instrument. The EQ-5D-5L encompasses 5 domains, asking patients to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: &quot;no problems&quot; (Level 1), &quot;slight problems&quot; (Level 2), &quot;moderate problems&quot; (Level 3), &quot;severe problems&quot; (Level 4), and &quot;extreme problems&quot; (Level 5). Each domain is assigned a level, and levels are combined to create a 5-digit number describing the patient's health state. For each patient, an index value is determined from a published country-specific value set. This index value or utility score ranges from 0 to 1.00 (with 1.0 representing perfect health) and is used in the calculation of quality-adjusted life years (QALYs) that are used to inform economic valuations of health interventions. A positive change from baseline indicates improvement.</description>
          <population>Intent-to-treat population (all randomized patients with patients analyzed according to the study drug assigned) with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.007" spread="0.1010"/>
                    <measurement group_id="O2" value="-0.011" spread="0.1010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in EQ-5D-5L in Cohort With no Germline BRCA</title>
        <description>EQ-5D-5L is a well-validated, general preference-based, health-related QoL instrument. The EQ-5D-5L encompasses 5 domains, asking patients to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: &quot;no problems&quot; (Level 1), &quot;slight problems&quot; (Level 2), &quot;moderate problems&quot; (Level 3), &quot;severe problems&quot; (Level 4), and &quot;extreme problems&quot; (Level 5). Each domain is assigned a level, and levels are combined to create a 5-digit number describing the patient's health state. For each patient, an index value is determined from a published country-specific value set. This index value or utility score ranges from 0 to 1.00 (with 1.0 representing perfect health) and is used in the calculation of quality-adjusted life years (QALYs) that are used to inform economic valuations of health interventions. A positive change from baseline indicates improvement.</description>
        <time_frame>At Cycle 4</time_frame>
        <population>Intent-to-treat population (all randomized patients with patients analyzed according to the study drug assigned) with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-gBRCA Niraparib</title>
            <description>Niraparib (300 mg) once daily in 28-day cycles until disease progression in patients without germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
          <group group_id="O2">
            <title>Non-gBRCA Placebo</title>
            <description>Placebo once daily in 28-day cycles until disease progression in patients without germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in EQ-5D-5L in Cohort With no Germline BRCA</title>
          <description>EQ-5D-5L is a well-validated, general preference-based, health-related QoL instrument. The EQ-5D-5L encompasses 5 domains, asking patients to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: &quot;no problems&quot; (Level 1), &quot;slight problems&quot; (Level 2), &quot;moderate problems&quot; (Level 3), &quot;severe problems&quot; (Level 4), and &quot;extreme problems&quot; (Level 5). Each domain is assigned a level, and levels are combined to create a 5-digit number describing the patient's health state. For each patient, an index value is determined from a published country-specific value set. This index value or utility score ranges from 0 to 1.00 (with 1.0 representing perfect health) and is used in the calculation of quality-adjusted life years (QALYs) that are used to inform economic valuations of health interventions. A positive change from baseline indicates improvement.</description>
          <population>Intent-to-treat population (all randomized patients with patients analyzed according to the study drug assigned) with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.004" spread="0.1077"/>
                    <measurement group_id="O2" value="-0.014" spread="0.0870"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in EQ-5D-5L in Cohort With no Germline BRCA</title>
        <description>EQ-5D-5L is a well-validated, general preference-based, health-related QoL instrument. The EQ-5D-5L encompasses 5 domains, asking patients to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: &quot;no problems&quot; (Level 1), &quot;slight problems&quot; (Level 2), &quot;moderate problems&quot; (Level 3), &quot;severe problems&quot; (Level 4), and &quot;extreme problems&quot; (Level 5). Each domain is assigned a level, and levels are combined to create a 5-digit number describing the patient's health state. For each patient, an index value is determined from a published country-specific value set. This index value or utility score ranges from 0 to 1.00 (with 1.0 representing perfect health) and is used in the calculation of quality-adjusted life years (QALYs) that are used to inform economic valuations of health interventions. A positive change from baseline indicates improvement.</description>
        <time_frame>At Cycle 6</time_frame>
        <population>Intent-to-treat population (all randomized patients with patients analyzed according to the study drug assigned) with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-gBRCA Niraparib</title>
            <description>Niraparib (300 mg) once daily in 28-day cycles until disease progression in patients without germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
          <group group_id="O2">
            <title>Non-gBRCA Placebo</title>
            <description>Placebo once daily in 28-day cycles until disease progression in patients without germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in EQ-5D-5L in Cohort With no Germline BRCA</title>
          <description>EQ-5D-5L is a well-validated, general preference-based, health-related QoL instrument. The EQ-5D-5L encompasses 5 domains, asking patients to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: &quot;no problems&quot; (Level 1), &quot;slight problems&quot; (Level 2), &quot;moderate problems&quot; (Level 3), &quot;severe problems&quot; (Level 4), and &quot;extreme problems&quot; (Level 5). Each domain is assigned a level, and levels are combined to create a 5-digit number describing the patient's health state. For each patient, an index value is determined from a published country-specific value set. This index value or utility score ranges from 0 to 1.00 (with 1.0 representing perfect health) and is used in the calculation of quality-adjusted life years (QALYs) that are used to inform economic valuations of health interventions. A positive change from baseline indicates improvement.</description>
          <population>Intent-to-treat population (all randomized patients with patients analyzed according to the study drug assigned) with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.005" spread="0.1097"/>
                    <measurement group_id="O2" value="-0.011" spread="0.0949"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in EQ-5D-5L in Cohort With no Germline BRCA</title>
        <description>EQ-5D-5L is a well-validated, general preference-based, health-related QoL instrument. The EQ-5D-5L encompasses 5 domains, asking patients to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: &quot;no problems&quot; (Level 1), &quot;slight problems&quot; (Level 2), &quot;moderate problems&quot; (Level 3), &quot;severe problems&quot; (Level 4), and &quot;extreme problems&quot; (Level 5). Each domain is assigned a level, and levels are combined to create a 5-digit number describing the patient's health state. For each patient, an index value is determined from a published country-specific value set. This index value or utility score ranges from 0 to 1.00 (with 1.0 representing perfect health) and is used in the calculation of quality-adjusted life years (QALYs) that are used to inform economic valuations of health interventions. A positive change from baseline indicates improvement.</description>
        <time_frame>At Post Progression</time_frame>
        <population>Intent-to-treat population (all randomized patients with patients analyzed according to the study drug assigned) with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-gBRCA Niraparib</title>
            <description>Niraparib (300 mg) once daily in 28-day cycles until disease progression in patients without germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
          <group group_id="O2">
            <title>Non-gBRCA Placebo</title>
            <description>Placebo once daily in 28-day cycles until disease progression in patients without germline BRCA mutation Niraparib vs. Placebo 2:1 ratio</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in EQ-5D-5L in Cohort With no Germline BRCA</title>
          <description>EQ-5D-5L is a well-validated, general preference-based, health-related QoL instrument. The EQ-5D-5L encompasses 5 domains, asking patients to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: &quot;no problems&quot; (Level 1), &quot;slight problems&quot; (Level 2), &quot;moderate problems&quot; (Level 3), &quot;severe problems&quot; (Level 4), and &quot;extreme problems&quot; (Level 5). Each domain is assigned a level, and levels are combined to create a 5-digit number describing the patient's health state. For each patient, an index value is determined from a published country-specific value set. This index value or utility score ranges from 0 to 1.00 (with 1.0 representing perfect health) and is used in the calculation of quality-adjusted life years (QALYs) that are used to inform economic valuations of health interventions. A positive change from baseline indicates improvement.</description>
          <population>Intent-to-treat population (all randomized patients with patients analyzed according to the study drug assigned) with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.042" spread="0.1465"/>
                    <measurement group_id="O2" value="-0.052" spread="0.1354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First day of treatment until 30 days after the last dose (Median days on treatment: Niraparib=250 and Placebo=163)</time_frame>
      <desc>Incidence of TEAEs were similar in the gBRCAmut and non-gBRCAmut cohorts. Safety data was therefore combined across cohorts for each treatment group to allow for more precise estimates of AE incidence and signal detection.</desc>
      <group_list>
        <group group_id="E1">
          <title>Niraparib</title>
          <description>Niraparib (300 mg) once daily in 28-day cycles until disease progression in patients. Niraparib vs. Placebo 2:1 ratio</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo once daily in 28-day cycles until disease progression in patients. Niraparib vs. Placebo 2:1 ratio</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Sinus Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Obstruction gastric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Disease Progression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactoid reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Post procedural discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Transfusion reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Metastases to peritoneum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Undifferentiated sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Metastates to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Ovarian cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Pain management</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Mastectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="367" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="171" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="163" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="178" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="270" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="145" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="125" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="168" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Blood Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Musculoskeletal apin</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Data for progression-free survival 2 (PFS2) was not mature at the data cut for the primary analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chief Medical Officier</name_or_title>
      <organization>TESARO</organization>
      <phone>781-257-2536</phone>
      <email>officeofcmo@tesarobio.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

